LLY Surges 6% on Monster Q2 Beat: Buy, Sell, or Hold?
Eli Lilly (LLY) Stock: A Simple Guide to the Pharmaceutical Giant’s Latest Results and Future Prospects
Quick Summary for Busy Readers
Eli Lilly’s stock jumped 5.8% after amazing Q2 results. The company makes Mounjaro (diabetes) and Zepbound (weight loss) — two of the fastest-growing drugs ever. They’re also launching Foundayo, a new pill version (no needles!), and developing even better next-gen medicines. The stock is pricey but has huge growth potential. Current verdict: Hold — buy on dips.
What Just Happened? (Q2 Results Explained Simply)
Imagine a lemonade stand that made $22.97 billion in one quarter — that’s 48% more than last year! Here’s the scorecard:
| Metric | Result | vs. Expectations |
|---|---|---|
| Revenue | $22.97 billion | Beat estimates |
| Adjusted EPS | $8.38 per share | Beat estimates (33% growth) |
| Stock Reaction | +5.8% since Aug 5 | Positive |
The superstars: Mounjaro (diabetes) and Zepbound (obesity) — together they bring in 65% of all revenue.
Important Point: One quarter doesn’t make a long-term investment. Smart investors look at the big picture — strengths, weaknesses, and where the company is headed.
Why Lilly’s GLP-1 Drugs Are a Big Deal
What Are GLP-1 Drugs? (ELI5)
Think of GLP-1 as a natural "fullness hormone" in your body. These drugs mimic it, telling your brain: "Hey, you’re full — stop eating!" They also help control blood sugar. Two birds, one stone!
The Dynamic Duo: Mounjaro & Zepbound
- Mounjaro → Approved for Type 2 Diabetes
- Zepbound → Approved for Weight Loss (Obesity)
- Combined H1 2026 sales: $27.6 billion
- Growing fast in the U.S. AND internationally
New Kid on the Block: Foundayo (The Pill!)
- First full quarter (Q2): $98 million in sales
- Game changer: It’s a once-daily PILL — no weekly shots needed!
- Covered by all 3 major PBMs (Pharmacy Benefit Managers = the companies that decide what insurance pays for)
- Expanding to 40+ countries — global launch by 2027
Medicare Just Opened the Floodgates
Starting July 2026, Medicare Part D covers:
- Zepbound for weight management
- Foundayo for weight management
- Mounjaro already covered for diabetes
Why this matters: Millions of older Americans can now afford these drugs. Huge new customer base unlocked!
The Future Pipeline: What’s Cooking in the Lab?
Lilly isn’t resting on its laurels. They’re building next-gen drugs:
| Drug | What’s Special | Status |
|---|---|---|
| Retatrutide | Triple threat! Hits 3 pathways (GLP-1 + GIP + Glucagon) → potentially more weight loss & better metabolic benefits | Phase 3 done. FDA submission Q1 2027 |
| Foundayo (more uses) | Testing for 6 other conditions (diabetes complications, etc.) | Phase 3 ongoing, data coming soon |
| Oral pipeline | More convenient pills in development | Various stages |
Retatrutide could be another multi-billion dollar blockbuster. Early data shows "profound" weight loss and improvements in:
- Blood sugar (A1C)
- Heart risk factors
- Knee arthritis pain
- Sleep apnea
- Liver disease (MASH)
Beyond GLP-1: Lilly Is Diversifying (Smart Move!)
Don’t put all eggs in one basket. Lilly gets it.
Newer Drugs Already Approved & Growing:
| Drug | For What? | Q2 Growth |
|---|---|---|
| Omvoh | Ulcerative colitis & Crohn’s | Contributing |
| Jaypirca | Blood cancers (lymphoma/leukemia) | Contributing |
| Ebglyss | Severe eczema | Contributing |
| Kisunla (donanemab) | Early Alzheimer’s | Contributing |
| Inluriyo (imlunestrant) | Metastatic breast cancer | Contributing |
Non-GLP-1 revenue grew 121% in Q2!
Shopping Spree: $20B+ in Biotech Deals This Year Alone
Buying companies in:
- Gene editing
- Cell therapy
- Neuroscience
- Cardiovascular
- Vaccines
- Oncology & inflammation
Translation: Building a fortress of future growth beyond just diabetes/obesity.
The Competition Is Heating Up
Big Rival: Novo Nordisk (NVO)
- Launched oral Wegovy pill in Jan 2026
- Q2 sales: ~$500 million
- 2.9 million prescriptions in Q2 alone
- First mover advantage in oral obesity pills
Hungry Upstarts:
| Company | Drug | Approach |
|---|---|---|
| Viking Therapeutics (VKTX) | VK2735 | Dual GIP/GLP-1 agonist — pill AND shot versions, Phase 3 start Q4 2026 |
| Structure Therapeutics (GPCR) | Aleniglipron | Once-daily oral GLP-1 pill — Phase 3 started |
Bottom line: Lilly leads now, but the race for the best pill is on. Convenience wins patients!
Valuation: Is the Stock Expensive? (Yes, But…)
Price-to-Earnings (P/E) Ratio — The "Price Tag" Metric
| Lilly | Industry Average | Lilly’s 5-Year Average | |
|---|---|---|---|
| Forward P/E | 27.99x | 18.47x | 34.57x |
Translation: You pay $28 for $1 of future earnings vs. $18.50 for average pharma. Premium price. BUT — cheaper than its own 5-year average ($34.57).
Analysts Are Getting More Optimistic
| Year | Old Estimate | New Estimate | Change |
|---|---|---|---|
| 2026 EPS | $34.55 | $35.93 | +$1.38 ↑ |
| 2027 EPS | $45.10 | $45.87 | +$0.77 ↑ |
Estimates rising = analysts see more profit coming.
Stock Performance Check
- YTD 2026: LLY +9.8% vs Industry +11.5%
- Slightly lagging peers this year despite great results
The "But Wait…" Section: Risks & Headwinds
Every investment has risks. Here are Lilly’s:
- Price Pressure: U.S. drug prices declining — drag on revenue (low-to-mid teens % in 2026)
- Fierce GLP-1 Competition: Novo’s oral pill, new entrants (Viking, Structure)
- Older Drugs Fading: Trulicity, Taltz, Verzenio — flat to down in 2026 (patents expiring)
- Slower H2 2026 Expected:
- No repeat of Q1/Q2 rebate accounting benefits
- Tough comparison to last year’s international launches
- Summer vacation slowdown in Europe
- Typical Q4 diabetes seasonality
- But: Absolute dollar growth still significant
Final Verdict: What Should YOU Do?
If You Already Own LLY (Zacks Rank #3 = Hold)
DON’T PANIC SELL. Stay invested.
- Dominant in massive, growing markets (obesity/diabetes)
- Diversified pipeline + aggressive M&A
- Strong financials + rising estimates
- Long-term story intact
If You’re Thinking of Buying
WAIT FOR A PULLBACK. Don’t chase at current highs.
- Stock trades at premium valuation
- Accumulate on market corrections (dips)
- Better entry points = higher future returns
Summary: The Big Picture in 5 Bullets
- Q2 Crushed It: 48% revenue growth, 33% EPS growth, raised guidance again
- GLP-1 Empire: Mounjaro + Zepbound = 65% of revenue, growing fast globally
- Pill Revolution: Foundayo (oral) off to strong start, Medicare access = huge tailwind
- Pipeline Power: Retatrutide (triple agonist) + diversification into neuro/oncology/immunology
- But Watch: Valuation premium, pricing pressure, competition, H2 slowdown optics
FAQ: Your Burning Questions Answered
1. What does "GLP-1" actually mean?
GLP-1 = Glucagon-Like Peptide-1. It’s a natural hormone your gut makes when you eat. It tells your brain "I’m full" and tells your pancreas "release insulin." The drugs copy this hormone — supercharged version.
2. Why is an oral pill (Foundayo) such a big deal?
Convenience! Current drugs (Mounjaro, Zepbound, Wegovy) are weekly injections. Many people hate needles. A once-daily pill = way more people willing to try it = massive market expansion.
3. What is "Retatrutide" and why the hype?
It’s a "triple agonist" — hits 3 hormone pathways at once (GLP-1 + GIP + Glucagon). Current drugs hit 1 or 2. Early data shows more weight loss + better metabolic health. Could be the most powerful obesity drug ever if approved.
4. Is Lilly just a "weight loss stock" now?
No! That’s the old story. Now:
- 65% GLP-1 (diabetes + obesity)
- 35% and growing fast from: immunology, oncology, neuroscience, new Alzheimer’s drug, new cancer drugs, etc.
- $20B+ in acquisitions to build non-GLP-1 future
5. Should I buy LLY stock today?
Depends on your style:
- Long-term believer? Consider starting a position, but use limit orders on dips.
- Value-focused? Too expensive (P/E 28 vs 18 industry). Wait for correction.
- Momentum trader? Already up big multi-year — may be due for consolidation.
- Always: Do your own research / consult a financial advisor.
Key Takeaway
Eli Lilly is a pharmaceutical powerhouse executing at an elite level. They own the two hottest drug franchises on the planet (Mounjaro/Zepbound), are first-to-market with an oral GLP-1 pill (Foundayo), have a mind-blowing pipeline (retatrutide), and are smartly diversifying via M&A.
The stock deserves a premium price. Whether it’s too premium today is the only debate. Long-term holders: sleep well. New buyers: be patient.
Disclaimer: This article is for educational purposes only. Not financial advice. Data sourced from Zacks Investment Research analysis of Eli Lilly’s Q2 2026 results and subsequent developments. Always conduct your own due diligence before investing.